Practice Changing: High-Dose Radiation Not Superior in NSCLC

Image via WikipediaPractice Changing: High-Dose Radiation Not Superior in NSCLC

A landmark trial in nonsmall-cell lung cancer (NSCLC) has found that high-dose conformal radiotherapy (74 Gy) did not improve survival, compared with the standard dose (60 Gy), in patients with unresectable stage III disease.

In fact, median overall survival was better with the standard dose than with the high dose...........

Related articles

• FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC (medicalxpress.com)
• Roche's Tarceva Receives European Approval For First-Line Use In A Genetically Distinct Type Of Lung Cancer (bioresearchonline.com)